title: FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.
abstract: The enzyme mTOR (mammalian target of rapamycin) is a major target for therapeutic intervention to treat many human diseases, including cancer, but very little is known about the processes that control levels of mTOR protein. Here, we show that mTOR is targeted for ubiquitination and consequent degradation by binding to the tumor suppressor protein FBXW7. Human breast cancer cell lines and primary tumors showed a reciprocal relation between loss of FBXW7 and deletion or mutation of PTEN (phosphatase and tensin homolog), which also activates mTOR. Tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, which suggests that loss of FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.
authors.affiliation: Cancer Research Institute, University of California at San Francisco, 2340 Sutter Street, San Francisco, CA 94143, USA.
authors.forename: Jian-Hua
authors.initials: JH
authors.lastname: Mao
authors.forename: Il-Jin
authors.initials: IJ
authors.lastname: Kim
authors.forename: Di
authors.initials: D
authors.lastname: Wu
authors.forename: Joan
authors.initials: J
authors.lastname: Climent
authors.forename: Hio Chung
authors.initials: HC
authors.lastname: Kang
authors.forename: Reyno
authors.initials: R
authors.lastname: DelRosario
authors.forename: Allan
authors.initials: A
authors.lastname: Balmain
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D018797:Cell Cycle Proteins / Q000235:genetics / Q000378:metabolism*; D002460:Cell Line; D045744:Cell Line, Tumor; D044783:F-Box Proteins / Q000235:genetics / Q000378:metabolism*; D000073979:F-Box-WD Repeat-Containing Protein 7; D017353:Gene Deletion; D018628:Gene Dosage; D020868:Gene Silencing; D016147:Genes, Tumor Suppressor; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009154:Mutation; D009368:Neoplasm Transplantation; D051059:PTEN Phosphohydrolase / Q000235:genetics / Q000378:metabolism*; D010766:Phosphorylation; D011485:Protein Binding; D011494:Protein Kinases / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D015398:Signal Transduction; D020123:Sirolimus / Q000494:pharmacology / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases; D014162:Transfection; D025521:Tumor Suppressor Proteins / Q000378:metabolism*; D044767:Ubiquitin-Protein Ligases / Q000235:genetics / Q000378:metabolism*; D054875:Ubiquitination
chemical_list: D018797:Cell Cycle Proteins; D044783:F-Box Proteins; D000073979:F-Box-WD Repeat-Containing Protein 7; C513273:FBXW7 protein, human; D025521:Tumor Suppressor Proteins; D044767:Ubiquitin-Protein Ligases; D011494:Protein Kinases; C546842:MTOR protein, human; C546843:mTOR protein, mouse; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human; D020123:Sirolimus
references.citation: Mol Cell Biol. 2001 Nov;21(21):7403-15
references.pmid: 11585921
references.citation: Cancer Res. 2007 Jan 15;67(2):818-26
references.pmid: 17234794
references.citation: Cancer Res. 2005 Dec 15;65(24):11361-6
references.pmid: 16357143
references.citation: BMC Cancer. 2006 Apr 18;6:96
references.pmid: 16620391
references.citation: EMBO J. 2004 May 19;23(10):2116-25
references.pmid: 15103331
references.citation: Oncogene. 2003 Nov 20;22(52):8379-85
references.pmid: 14627978
references.citation: Oncogene. 2008 Jul 3;27(29):4086-95
references.pmid: 18332865
references.citation: Cancer Cell. 2006 Dec;10(6):515-27
references.pmid: 17157791
references.citation: Cancer Cell. 2006 Dec;10(6):529-41
references.pmid: 17157792
references.citation: Curr Biol. 2004 Oct 26;14(20):1852-7
references.pmid: 15498494
references.citation: Nature. 2001 Sep 20;413(6853):316-22
references.pmid: 11565034
references.citation: Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9085-90
references.pmid: 15150404
references.citation: Curr Cancer Drug Targets. 2005 Feb;5(1):57-68
references.pmid: 15720190
references.citation: Nat Genet. 1998 Aug;19(4):348-55
references.pmid: 9697695
references.citation: Nature. 2004 Mar 4;428(6978):77-81
references.pmid: 14999283
references.citation: Cancer Res. 2007 Oct 1;67(19):9006-12
references.pmid: 17909001
references.citation: Nature. 2004 Dec 9;432(7018):775-9
references.pmid: 15592418
references.citation: Nat Rev Cancer. 2008 Feb;8(2):83-93
references.pmid: 18094723